Abstract
Preliminary data suggest potential benefit of 5-HT receptor agonists in the treatment of ataxias. We studied the effects of buspirone in a cohort of twenty patients with spinocerebellar ataxia (SCA). Twenty patients were treated in this double-blind, placebo controlled, cross-over trial with either buspirone HCl 30 mg twice daily or placebo for 3 months. Buspirone was not shown to be superior to placebo in the treatment of patients with SCA. © 2007 Elsevier B.V. All rights reserved.
Cite
CITATION STYLE
Assadi, M., Campellone, J. V., Janson, C. G., Veloski, J. J., Schwartzman, R. J., & Leone, P. (2007). Treatment of spinocerebellar ataxia with buspirone. Journal of the Neurological Sciences, 260(1–2), 143–146. https://doi.org/10.1016/j.jns.2007.04.019
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
